PERSPECTIVE’S [212PB]BAMZIREOTIDE NAVOXETAN (VMT-Α-NET) DEMONSTRATES ENCOURAGING SAFETY, DURABLE DISEASE CONTROL, AND ROBUST TUMOR RESPONSE ACROSS MULTIPLE DOSE COHORTS IN PHASE 1/2A TRIAL IN ADVANCED SSTR2-EXPRESSING NETS

Reuters · 2d ago

Please log in to view news